{"symbol":"BMY","fiscalQuarter":"Q4-2019","reportDate":"2020-02-06","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2019","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 2.3%","keyNumbers":[{"metric":"EPS","actual":"$1.22","expected":"N/A","surprise":"+29.96%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite not providing revenue figures.","The focus remains on long-term growth and pipeline development."],"summary":"Management highlighted the strong EPS results as a positive sign. They emphasized their commitment to advancing their product pipeline."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's strong EPS performance indicates effective cost management and operational efficiency. The stock rose by 2.3%, reflecting investor confidence in the company's future prospects, despite the lack of revenue data and guidance. The positive surprise in EPS suggests that the company is on the right track, even as it navigates uncertainties in the market.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2019 earnings: EPS beat by 29.96%. Stock up 2.3%. Full breakdown."}}